Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis

doi:10.5306/wjco.v14.i11.445

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2532)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1232

Figures (1-3)

161

Tables (1-4)

131

Sum=1579

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

133

Download

343

Sum=476

Publishing Process of This Article

Item

Count

Browse

100

Download

308

Sum=408

Nov 24, 2023 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Nov 24, 2023; 14(11): 445-458
Published online Nov 24, 2023. doi: 10.5306/wjco.v14.i11.445

Table 4 Treatment methods of brain metastasis

Item	Patients with BM (n = 68)	Median survival time (mo)
Medication	7	12
MDT	27	21
Local therapy alone	30	15
Neither	4
Local therapy	n = 57
SRT alone	19	16
Surgery + SRT	6	19
SRT + WBRT	10	18
Surgery + WBRT	3	30
WBRT	17	12
Surgery + SRT + WBRT	2	21
HER2 targeted therapy	n = 16
Trastuzumab	5	17
Trastuzumab + pertuzumab	2
Trastuzumab + TKI	2	23
Capecitabine + TKI	7	54

MDT: Multidisciplinary treatment; WBRT: Whole brain radiation therapy; SRT: Stereotactic radiotherapy; TKI: Trastuzumab plus tyrosine kinase inhibitors; BM: Brain Metastasis; HER2: Human epidermal growth factor receptor 2.

Citation: Chen YR, Xu ZX, Jiang LX, Dong ZW, Yu PF, Zhang Z, Gu GL. Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis. World J Clin Oncol 2023; 14(11): 445-458
URL: https://www.wjgnet.com/2218-4333/full/v14/i11/445.htm
DOI: https://dx.doi.org/10.5306/wjco.v14.i11.445